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Overview	  
The	  purpose	  of	  this	  retrospective	  study	  is	  to	  compare	  the	  presentation	  and	  treatment	  outcomes	  in	  
patients	  presenting	  with	  Epithelial	  Salivary	  Gland	  Tumours	  in	  the	  Anti	  retroviral	  treatment	  (ART)	  era	  
presenting	  to	  Inkosi	  Albert	  Luthuli	  Hospital	  from	  January	  2003	  to	  June	  2017.	  	  
HIV	  is	  a	  global	  pandemic	  with	  an	  estimated	  36.7	  million	  people	  infected	  worldwide	  with	  HIV	  in	  2015.	  
Sub	  Saharan	  Africa	  remains	  the	  region	  most	  heavily	  affected	  with	  South	  Africa	  being	  home	  to	  the	  
world’s	  largest	  population	  living	  with	  HIV	  –	  which	  in	  2016	  was	  estimated	  at	  7.1	  million	  people.	  Data	  
released	  in	  2018	  by	  Stats	  SA	  placed	  HIV	  prevalence	  rates	  in	  South	  Africa	  at	  13.1%	  and	  19	  %	  for	  adults	  
aged	  15	  –	  49	  years.	  Anti	  retroviral	  therapy	  has	  changed	  the	  face	  of	  the	  HIV	  pandemic	  with	  people	  
infected	  with	  HIV	  now	  presenting	  with	  a	  wide	  variety	  of	  conditions	  including	  Non	  –	  AIDS	  defining	  
cancers	  in	  the	  Head	  and	  Neck	  region.	  There	  are	  various	  Head	  and	  Neck	  sites	  that	  have	  been	  
investigated	  but	  little	  data	  exists	  regarding	  the	  impact	  of	  HIV	  on	  the	  Salivary	  Gland	  subset	  of	  Head	  and	  
Neck	  Tumours.	  In	  particular	  there	  is	  no	  data	  on	  the	  topic	  from	  South	  Africa.	  Kwazulu	  Natal’s	  high	  rates	  
of	  infection	  make	  it	  an	  excellent	  region	  in	  which	  to	  conduct	  the	  study.	  The	  study	  will	  further	  explore	  
epidemiology	  and	  the	  spectrum	  pathology	  of	  Epithelial	  Salivary	  Gland	  Neoplasms,	  in	  HIV	  positive	  and	  
negative	  patients,	  presenting	  to	  our	  institution	  and	  whether	  our	  data	  compares	  to	  our	  local	  and	  
international	  counterparts.	  	  
This	  study/	  project	  was	  conducted	  by	  performing	  a	  retrospective	  chart	  review	  to	  determine	  any	  
differences	  between	  patients	  with	  HIV	  presenting	  with	  Epithelial	  Salivary	  Gland	  Tumours	  and	  their	  HIV	  
negative	  counterparts.	  It	  further	  gathers	  information	  regarding	  patient	  presentation	  and	  outcomes	  
between	  HIV	  positive	  patients	  on	  ARV’s	  and	  those	  not	  on	  treatments.	  	  
It	  is	  hoped	  that	  this	  study	  will	  enlighten	  us	  to	  the	  trends	  in	  epidemiology	  of	  Salivary	  Gland	  Neoplasms	  
at	  our	  institution	  and	  aspects	  of	  Epithelial	  Salivary	  Gland	  Tumours	  in	  HIV	  positive	  individuals,	  
particularly	  in	  those	  on	  treatment	  and	  in	  doing	  so	  will	  enable	  us	  in	  future	  to	  faster	  recognize,	  diagnose	  
and	  better	  manage	  affected	  individuals.	  	  
iv	  
	  
Table	  of	  Contents	  
	  
	  
Declaration	  ...................................................................................................................................................	  ii	  
Overview	  .....................................................................................................................................................	  iii	  
Table	  of	  Contents	  ........................................................................................................................................	  iv	  
Chapter	  1:	  Introduction	  ................................................................................................................................	  5	  
Chapter	  2:	  A	  submission	  ready	  manuscript.	  ...............................................................................................	  19	  
Appendices	  .....................................................................................................	  Error!	  Bookmark	  not	  defined.	  
Appendix	  1:	  The	  final	  Study	  Protocol	  (Include	  the	  final	  protocol	  which	  was	  given	  full	  approval	  by	  Brec	  
and/or	  the	  postgrad	  office)	  ......................................................................................................................	  1	  
Appendix	  2:	  The	  Guidelines	  for	  Authorship	  for	  the	  Journal	  selected	  for	  submission	  of	  the	  manuscript	  X	  
Appendix	  3:	  Ethical	  approvals	  ..............................................................................................................	  XVII	  
Appendix	  4:	  Data	  collection	  tools	  	  .........................................................................................................	  XXI	  
Appendix	  5:	  Raw	  data	  	  .........................................................................................................................	  XXIII	  
Attachment	  1:	  Similarity	  report	  	  









Salivary	  Gland	  Neoplasms	  are	  an	  uncommon	  entity	  being	  less	  than	  3%	  of	  all	  tumours	  and	  3	  –	  
10%	  of	   all	  Head	   and	  Neck	   Tumours.1,2	  Despite	   this,	   they	   represent	   a	  wide	   variety	   of	   both	  
malignant	  and	  benign	  subtypes.	  Epithelial	  salivary	  gland	  tumours	  represent	  more	  than	  90%	  
of	  salivary	  gland	  tumours	  and	  can	  occur	   in	  both	  the	  major	  and	  minor	  salivary	  glands.3	  The	  
occurrence	  of	   these	   tumours	  within	   the	  parotid	   and	   submandibular	   glands	   (major	   salivary	  
glands)	  will	  be	  the	  focus	  of	  this	  study.	  	  
To	   date	   there	   are	   no	   studies	   out	   of	   Durban	   describing	   the	   spectrum	   of	   Parotid	   and	  
Submandibular	  Gland	  pathology.	   This	   study	  will	   further,	   in	  addition,	  explore	   the	  effects	  of	  
human	  immunodeficiency	  virus	  (HIV)	  infection	  on	  this	  subset	  of	  tumours,	  knowledge	  which	  
has	  not	  been	  reported	  on	  previously	  in	  literature	  in	  South	  Africa	  or	  internationally.	  	  
ANATOMY	  OF	  THE	  PAROTID	  AND	  SUBMANDIBULAR	  GLANDS	  
The	  Parotid	  Gland	  
This	   paired	   gland	   has	   two	   lobes,	   a	   larger	   superficial	   lobe	   and	   a	   smaller,	   deep	   lobe	  
demarcated	   from	   each	   other	   by	   the	   facial	   nerve.	   The	   facial	   nerve	   branches	   within	   the	  
substance	  of	  the	  gland	  and	  can	  vary	  in	  its	  branching	  pattern	  making	  each	  surgical	  dissection	  
unique	   and	   challenging.	   Around	   80%	   of	   tumours	   arising	   from	   the	   parotid	   gland	   originate	  
from	  within	   the	   superficial	   lobe	  of	   the	   gland.	  Only	   20%	  arise	   from	  or	   grow	   to	   involve	   the	  
deep	  lobe	  of	  the	  gland.1	  	  
The	  Submandibular	  Gland	  
This	  paired	  gland	  is	  located	  in	  the	  anterior	  part	  of	  the	  submandibular	  triangle	  of	  the	  neck.	  Its	  
relation	  to	  the	  mylohyoid	  muscle	  determines	  the	  superficial	  and	  deep	  parts	  of	  the	  gland.	  The	  




the	  mandible.	  The	  deep	  portion	  wraps	  around	  the	  posterior	  margin	  of	  the	  mylohyoid	  muscle	  
to	  lie	  lateral	  on	  the	  surface	  of	  the	  hyoglossus	  muscle	  and	  lateral	  to	  the	  root	  of	  the	  tongue.1	  	  
PRESENTATION	  OF	  SALIVARY	  GLAND	  TUMOURS	  
Majority	  of	   tumours	   that	  develop	  within	   the	  parotid	  and	  submandibular	  glands	  commonly	  
develop	   over	   a	   long	   period	   of	   time.	   In	   general,	   they	   continue	   to	   grow	   slowly	   and	   do	   not	  
cause	   any	   further	   symptoms.	   Should	   pain	   or	   nerve	   palsy	   accompany	   the	   mass	   then	   a	  
malignant	   neoplasm	   should	   be	   considered.1Parotid	   tumours	   commonly	   present	   in	   the	  
retromandibular	  region,	  posterior	  to	  the	  angle	  of	  the	  mandible	  or	  on	  the	  cheek	  anterior	  to	  
the	  tragus	  of	  the	  ear.	  Submandibular	  gland	  tumours	  present	  in	  the	  submandibular	  triangle	  of	  
the	  neck	  and	  constitute	  10–15%	  of	  all	  salivary	  gland	  tumours.	  The	  rest	  of	  tumours	  arise	  from	  
the	   remaining	   glands,	   which	   include	   the	   paired	   sublingual	   salivary	   glands	   and	   the	   minor	  
salivary	   glands.	  Malignant	   Salivary	  Gland	   tumours	  usually	   present	   in	   the	  6th	   decade	  of	   life	  
and	  benign	   lesions	   in	  the	  4th	  decade	  of	   life.	  There	   is	  a	  slight	  female	  predominance	  when	  it	  
comes	  to	  benign	  tumours	  but	  equal	  distribution	  amongst	  males	  and	  females	  when	  it	  comes	  
to	  malignant	  lesions.1,4	  	  
DIAGNOSIS	  OF	  SALIVARY	  GLAND	  TUMOURS	  	  
Fine	  Needle	  Aspiration	  Cytology	  
Pre–operative	  diagnosis	  of	  salivary	  gland	  tumours	  by	  fine	  needle	  aspiration	  cytology	  (FNAC)	  
can	  be	  useful	  in	  establishing	  whether	  a	  lesion	  is	  inflammatory	  or	  neoplastic,	  a	  lymphoma,	  an	  
epithelial	  malignancy,	  or	  represents	  a	  metastasis	  or	  a	  primary	  tumour.5	  This	  is	  especially	  true	  
for	   the	   submandibular	   masses	   as	   few	   submandibular	   triangle	   masses	   arise	   from	   the	  
submandibular	   gland.	   Majority	   of	   lesions	   in	   this	   area	   are	   secondary	   to	   an	   inflammatory	  
process	   or	   represent	   neoplasms	   originating	   from	   lymph	   nodes	   in	   the	   area.	   FNAC	   can	   be	  
useful	  in	  distinguishing	  this	  and	  assist	  in	  directing	  appropriate	  therapy.4,5,6	  The	  use	  of	  FNAC	  
in	   parotid	   tumours	   remains	   controversial.3,5,6	   The	   area	   sampled	   may	   miss	   the	   area	   of	  
malignant	   change	   within	   the	   mass.	   FNAC	   sampling	   can	   reveal	   the	   presence	   of	   normal	  
lymphocytes	  which	  can	  be	  found	  in	   lymphoma,	  Warthin’s	  tumour,	  benign	  lymphoepithelial	  
disease	  and	  tuberculosis,	  making	  it	  difficult	  to	  make	  a	  conclusive	  diagnosis	  on	  FNAC	  alone.	  It	  




that	  being	  surgery.	  Some	  surgeons	  feel	  that	  it	  is	  useful	  because	  knowledge	  of	  the	  histologic	  
type	  may	  be	  useful	  in	  counseling	  patients	  for	  more	  extensive	  surgery	  should	  results	  indicate	  
a	  high–grade	  malignancy.	  FNAC	  could	  also	  rule	  out	  some	  non	  –	  neoplastic	  causes	  of	  parotid	  
masses	  that	  do	  not	  need	  surgical	  management.	  In	  2007,	  Van	  Lierop	  et	  al7	  reported	  that	  the	  
accuracy	  of	  FNAC	  in	  predicting	  whether	  a	  mass	   is	  benign	  or	  malignant	  ranges	  from	  81%	  to	  
98%.7	  Further	  the	  risk	  associated	  with	  seeding	  of	  tumours	  is	  exceedingly	  small	  compared	  to	  
that	  of	  an	  open	  biopsy	  .1	  
Radiology	  
Radiological	  investigation	  in	  the	  form	  of	  computed	  tomography	  (CT)	  or	  magnetic	  resonance	  
imaging	   (MRI),	  especially	   for	  benign	  tumours,	  often	  does	   little	   to	  add	  to	   the	  diagnosis	  and	  
management.5	  Majority	  of	  tumours	  arising	  from	  both	  the	  submandibular	  and	  parotid	  gland	  
are	  managed	  without	   imaging.	   Imaging	  can	  take	  the	  form	  of	  CT	  or	  MRI	  as	  both	  have	  been	  
proven	   to	   be	   equally	   sensitive	   when	   investigating	   salivary	   gland	   neoplasms.1	   Imaging	   is	  
undertaken,	   in	   the	   case	   of	   the	   parotid	   gland,	   if	   the	  mass	   is	   arising	   from	   or	   extending	   to	  
involve	  the	  deep	  lobe	  of	  the	  gland,	  if	  there	  is	  facial	  weakness,	  pain	  or	  other	  neural	  deficit	  or	  
symptom	   suggestive	   of	  malignancy	   and	   if	   the	  mass	   is	   a	   congenital	   parotid	   tumour.	   In	   the	  
case	  of	  the	  submandibular	  gland	  imaging	  is	  undertaken	  if	  there	  is	  a	  regional	  neural	  deficit	  or	  
if	  the	  mass	  is	  fixed	  to	  the	  mandible.	  Imaging	  is	  further	  indicated	  if	  there	  is	  recurrent	  disease	  
in	  either	  of	  the	  glands.1	  
MANAGEMENT	  OF	  EPITHELIAL	  SALIVARY	  GLAND	  TUMOURS	  
Parotid	  Gland	  Tumour	  Management	  
Management	   of	   Benign	   Salivary	   Gland	   Neoplasms	   involves	   removal	   of	   the	  mass	   with	   the	  
associated	  part	  of	  the	  gland	  from	  which	  the	  tumour	  arises.	   In	  the	  case	  of	  a	  tumour	  arising	  
from	   the	   superficial	   lobe	   of	   the	   parotid	   a	   superficial	   parotidectomy	   is	   adequate.	   Tumours	  
arising	  from	  the	  deep	  lobe	  may	  need	  a	  total	  parotidectomy	  with	  sparing	  of	  the	  facial	  nerve	  .1	  
Malignant	   Parotid	   Tumours	   are	   best	   managed	   by	   primary	   surgery	   and	   where	   indicated,	  
postoperative	   radiotherapy.	   Chemotherapy,	   at	   present,	   has	   a	   very	   limited	   role	   in	   the	  
management	  of	  these	  tumours.	  The	  facial	  nerve	  should	  be	  spared	  in	  all	  cases	  of	   low-­‐grade	  




management	  of	   the	   facial	   nerve	   in	  high-­‐grade	   tumours.	   Some	   surgeons	  advocate	   that	   the	  
facial	   nerve	   should	   be	   spared	   if	   functioning	   preoperatively	   regardless	   of	   the	   histological	  
tumour	   type	   unless	   the	   nerve	   passes	   right	   through	   the	   tumour	   and	   cannot	   be	   dissected	  
during	   surgery.	  However,	   some	   surgeons	   still	   feel	   that	   the	  nerve	   should	  be	   resected	   in	  all	  
cases	  of	  high-­‐grade	  tumours.	  Radiotherapy	  is	  then	  indicated	  for	  all	  high-­‐grade	  tumours	  and	  
indicated	  for	  low-­‐grade	  tumours	  only	  if	  there	  is	  a	  positive	  margin	  or	  it	  is	  an	  advanced	  stage	  
tumour	  (T3/T4	  tumour).6	  	  
In	   the	   case	   of	   a	   high-­‐grade	   cancer,	   if	   there	   is	   concurrent	   nodal	   disease	   then	   a	   modified	  
radical	  neck	  dissection	  should	  be	  carried	  out.6	  
In	   the	   case	   of	   a	   high-­‐grade	   cancer	   with	   no	   concurrent	   nodal	   disease	   then	   elective	   neck	  
dissection	  should	  be	  performed	  with	  clearance	  of	  levels	  1	  -­‐3.6	  
The	  major	  complications	  associated	  with	  Parotid	  Gland	  Surgery	  are:	  1	  
• Facial	   Nerve	   injury	   –	   may	   be	   partial	   or	   complete	   or	   temporary	   or	   permanent.	   If	  
planned	  or	  unplanned	  sacrifice,	  then	  repair	  or	  grafting	  should	  be	  undertaken	  at	  the	  
same	  sitting.6	  Van	  Lierop	  et	  al7	  reported	  that	  temporary	  facial	  nerve	  palsy	  occurred	  
post-­‐surgery	   in	  46	  –	  63%	  of	  patients	  and	   the	   rates	  of	  permanent	   facial	  nerve	  palsy	  
post-­‐surgery	  was	   reported	  as	  3-­‐4	  %.	   In	  malignant	  disease	  where	  attempts	   to	   spare	  
the	   facial	   nerve	  were	  made,	   the	   reported	   incidence	  of	  permanent	  paralysis	  was	  as	  
high	   as	   36%.	   In	   South	  Africa,	   Van	   Lierop	   et	   al7	   reported	   a	   rate	   of	   temporary	   facial	  
nerve	  palsy	  related	  to	  benign	  disease	  as	  34%	  and	  a	  permanent	  palsy	  rate	  of	  3%	  for	  
benign	  disease	  and	  3%	   for	  malignant	  disease	  –	   rates	  well	  below	  most	  series	  out	  of	  
the	  western	  world.7	  However,	  it	  is	  important	  to	  note	  the	  series	  from	  South	  Africa	  was	  
a	   review	  of	  parotidectomies	  done	  by	  a	   single	   surgeon	  who	   is	  a	   specialist	  head	  and	  
neck	  surgeon	  with	  years	  of	  experience	  in	  managing	  salivary	  gland	  disease.	  	  
• Hematoma	   formation	   –	   surgical	   drains	   are	   used	   post	   operatively	   to	   reduce	   risk	   of	  
this,	  but	  should	  it	  occur	  the	  wound	  would	  have	  to	  be	  explored	  to	  locate	  the	  source	  
and	  evacuate	  the	  hematoma.	  
• Sialocoele	   or	   Salivary	   Fistula	   –	   this	   implies	   a	   connection	   between	   the	   skin	   and	   the	  
salivary	  gland	  or	  duct.	  The	  overall	   incidence	  of	  this	  complication	  has	  been	  reported	  




compression	  dressings	  or	  botulin	   toxin	   type	  A	  administration.	   Techniques	   involving	  
neurectomy	  have	  shown	  limited	  success	  and	  anticholinergic	  drugs	  have	  fallen	  out	  of	  
favor	  due	  to	  their	  distressing	  side	  effects.10	  
• Frey’s	   Syndrome/gustatory	   sweating	   -­‐	   this	   is	   the	   most	   common	   long-­‐term	  
complication	   and	   results	   in	   the	   patient	   having	   sweating	   and	   flushing	   with	   meals.	  
Usually	   becomes	   evident	   1	   to	   12	  months	   post	   procedure.	   The	   incidence	   of	   Frey’s	  
syndrome	  has	  been	  reported	  in	  some	  studies	  to	  be	  as	  high	  as	  50%	  but	  severe	  cases	  
have	   been	   reported	   to	   be	   around	   15%.	   If	   problematic	   to	   the	   patient	   once	   again	  
botulin	  toxin	  is	  administered,	  and	  should	  this	  method	  fail	  or	   if	  contraindicated	  then	  
surgery	  to	  disrupt	  the	  aberrant	  innervation	  is	  considered.10	  
Submandibular	  Gland	  Tumour	  Management	  
All	  tumours	  arising	  from	  this	  gland	  require	  total	  resection	  of	  the	  gland.	  	  
In	  the	  case	  if	  a	  high-­‐grade	  cancer,	  if	  there	  is	  concurrent	  nodal	  disease	  then	  a	  modified	  radical	  
neck	  dissection	  should	  be	  carried	  out	  .6	  	  	  
In	   the	   case	   of	   a	   high-­‐grade	   cancer	   with	   no	   concurrent	   nodal	   disease	   then	   elective	   neck	  
dissection	  should	  be	  performed	  with	  clearance	  of	  levels	  1	  -­‐3	  with	  additional	  clearance	  of	  the	  
submental	  triangle.6	  
Major	  complications	  of	  submandibular	  gland	  surgery:1	  
• Damage	  to	  the	  marginal	  mandibular	  branch	  of	  the	  facial	  nerve.	  Marginal	  mandibular	  
nerve	  paresis	  results	  in	  temporary	  or	  permanent	  weakness	  of	  the	  angle	  of	  the	  mouth	  
that	  will	   be	  most	  noticeable	  on	   smiling	   and	  puckering	   the	   lips.	  Overall	   incidence	   is	  
approximately	  7.7%.11	  	  	  
• Lingual	   and	   Hypoglassal	   Nerve	   Damage.	   The	   overall	   incidence	   of	   injury	   has	   been	  
reported	  as	  2.9	  %	  and	  1.4%	  respectively.11	  
SURGICAL	  RISK	  IN	  HIV	  POSITIVE	  PATIENTS	  
• In	   2009,	   Madiba	   et	   al12	   reported	   that	   HIV	   infection	   should	   not	   be	   considered	   a	  




advised	   that	   surgery	   should	  be	  offered	   to	  HIV	  positive	  patients,	   as	   it	  would	   to	  HIV	  
negative	  patients	  without	  the	  fear	  of	  an	  unfavorable	  outcome.12	  
CLASSIFICATION	  OF	  SALIVARY	  GLAND	  TUMOURS	  
The	  World	  Health	  Organization	   (WHO)	   classification	   of	   salivary	   gland	   cancers	   published	   in	  
2017	   listed	   11	   benign,	   1	   borderline	   tumour,	   4	   other	   epithelial	   lesions	   and	   22	   malignant	  
epithelial	  neoplasms.13	  They	  can	  further	  be	  separated	   into	  epithelial	   tumours,	   the	   focus	  of	  
this	  study,	  and	  stromal	  tumours.2	  	  
There	  are	  several	  studies	  on	  salivary	  gland	  neoplasms	  from	  different	  geographic	  areas	  of	  the	  
world.	  Table	  0.1	  represents	  pathology	  data	  from	  the	  North	  American	  population	  as	  reported	  
by	   Pinkston	   et	   al.14	   One	  would	   expect	   variation	   in	   incidence	   and	   histopathologic	   types	   of	  
salivary	   neoplasms	   pending	   the	   epidemiology	   of	   the	   population	   being	   studied.15	   This	   is	  
probably	  best	  highlighted	  when	  comparing	  the	  incidence	  of	  Warthin’s	  tumour	  in	  a	  European	  
and	  African	   study	   population,	  where	   the	   incidence	   of	  Warthin’s	   tumour	   is	   reduced	   in	   the	  
African	   population.15	   The	   African	   population	   has	   also	   been	   found	   to	   have	   an	   increased	  
malignant	   to	  benign	   ratio	  of	  parotid	   tumours	  when	  compared	   to	   the	  western	  world.7,15	   In	  
2009,	   Mejía-­‐Velázquez	   et	   al,16	   demonstrated	   that	   in	   the	   Mexican	   population	   malignant	  
tumours	  were	  found	  in	  younger	  age	  brackets	  than	  what	  was	  reported	  in	  the	  American	  and	  
European	  literature.16	  
Table	  0.1:	  Common	  Parotid	  Gland	  Tumours	  4	  
Histopathology	   Incidence	  (%)	  
Parotid	  Gland	   Submandibular	  
Pleomorphic	  Adenoma	   59	   36	  
Mucoepidermoid	  Carcinoma	   7.9	   25	  
Warthin’s	  Tumour	   7.3	   12	  
Carcinoma	  Ex	  –	  Pleomorphic	  Adenoma	   4.4	   10	  




Adenoid	  Cystic	  Carcinoma	   3.1	   7.0	  
Squamous	  Cell	  Carcinoma	   2.0	   1.0	  
	  
Chung	   et	   al17,	   in	   1999,	   reported	   on	   parotid	   gland	   tumours	   in	   an	   Asian	   population	   over	   a	  
period	   of	   10	   years.	   The	   racial	   distribution	   of	   Warthin's	   tumours	   exhibited	   an	   increased	  
incidence	  among	  Chinese	  patients	  and	  a	   reduced	   incidence	  amongst	   the	  Malay	  and	   Indian	  
populations.17,18	  
Bello	  et	  al19,	   in	  2012,	  reported	  that	  majority	  of	  malignant	  tumours	  occurred	   in	  the	  parotid	  
gland	   in	   the	   Finnish	   centers	   reviewed,	   whereas	   among	   the	   Israeli	   population	   reviewed,	  
malignant	   tumours	   were	   more	   commonly	   seen	   in	   the	   minor	   salivary	   glands,	   further	  
illustrating	  the	  differences	  that	  can	  occur.19	  	  
With	  regards	  to	  Africa,	  there	  are	  a	  number	  of	  significant	  differences	  in	  various	  parts	  of	  the	  
continent.	   An	   example	   of	   this	   is	   the	   proportion	   of	   malignant	   tumours	   arising	   from	   the	  
salivary	  gland	  which	  varies	  from	  as	  high	  as	  46%	  in	  Uganda	  to	  as	  low	  as	  16.7%	  in	  Senegal.15	  
In	  South	  Africa	  there	  are	  currently	  only	  four	  studies	  describing	  the	  spectrum	  of	  Parotid	  Gland	  
pathology	  and	  only	  two	  of	  those	  studies	  include	  the	  disease	  spectrum	  of	  the	  submandibular	  
gland.	  These	  are	  reviewed	  in	  the	  Table	  0.2.7,20-­‐22	  
In	  a	  review	  of	  these	  studies	  the	  rates	  of	  malignancy	  in	  the	  parotid	  gland	  ranged	  from	  24	  –	  29	  
%	  and	  10	  –	  19	  %	  in	  the	  submandibular	  gland.7,20-­‐22	   In	  the	  recent	  study	  by	  Van	  Lierop	  et	  al7	  
that	  looked	  exclusively	  at	  Parotid	  tumours	  excised	  by	  a	  single	  surgeon	  in	  Cape	  Town,	  South	  
Africa,	   they	   hypothesized	   that	   the	   possible	   reason	   for	   their	   higher	   rate	   of	   metastatic	  
cutaneous	  squamous	  cell	  carcinoma	  (SCC)	  was	  due	  to	  there	  being	  a	  high	  rate	  of	  skin	  cancer	  
in	  South	  Africa.	  Their	  hypothesis	  was	  confirmed	  with	  metastatic	  cutaneous	  SCC	  (22%)	  being	  
the	  most	  common	  malignant	  tumour	  reported	  from	  their	  study.	  These	  results	  were	  echoed	  
by	  similar	  trends	  in	  the	  Australian	  literature.	  Overall,	  studies	  from	  Uganda	  and	  Tanzania,	  on	  
parotid	  malignancy	   reported	  much	  higher	   rates	  of	  malignancy,	   46%	  and	  47%	   respectively.	  





As	  mentioned	  above,	  no	  studies	  out	  of	  South	  Africa	  have	  looked	  at	  what	  effect	  HIV	  infection	  
or	   anti–retroviral	   therapy	   has	   on	   salivary	   gland	   disease.	   Sub-­‐Saharan	   Africa	   remains	   the	  
region	  most	  heavily	  affected	  with	  South	  Africa	  being	  home	  to	  the	  world’s	  largest	  population	  
living	  with	  HIV	  –	  which	   in	   2016	  was	   estimated	  at	   7.1	  million	  people	  making	   this	   the	   ideal	  




Table	  0.2:	  Salivary	  gland	  lesions	  in	  South	  Africa.	  PG	  –	  parotid	  gland,	  SG	  –	  submandibular	  
gland,	  and	  MG	  –	  minor	  salivary	  gland.	  ca	  –	  cancer	  and	  NR	  –	  not	  reported	  
Type	   of	   Tumor	  
Cancer	  




































PG	  	   PG	  	   PG	  	   SG	  	   PG	  	   SG	  	   MG	  	  




54	   72	   75	   90	   75	  
Pleomorphic	  
Adenoma	  
42	   63	   68	   90	   63	  
Whartins	  Tumour	   8	   2	   3	   0	   7	  
Monomoprhic	  
Adenoma	  












20	   28	   24	   10	   25	  
Mucoepidermoid	  
ca	  
5	   3	   12	   0	   5	  
Acinic	  cell	  ca	   4	   0	   4	   0	   2	  
Adenoid	  cystic	  ca	   1.5	   15	   3	   7	   3	  






0	   0	   1	   0	   0	  
Adenocarcinoma	   0.5	   0	   1	   0	   2	  




0	   0	   1	   0	   5	  
Undifferentiated/o
ther	  




7	   NR	   1	   0	   NR	  
NON-­‐NEOPLASTIC	  
LESIONS	  
12	   NR	   NR	   NR	   NR	  
*	  IN	  THIS	  STUDY	  THE	  DETAILS	  OF	  PATHOLOGY	  ORIGINATING	  FROM	  EACH	  GLAND	  WERE	  NOT	  
CLEARLY	  OUTLINED.	  	  
THE	  LINK	  BETWEEN	  HIV	  AND	  EPITHELIAL	  SALIVARY	  GLAND	  NEOPLASMS.	  
The	  devastating	  effect	  of	  the	  global	  HIV	  epidemic	  has	  been	  significantly	  reduced	  largely	  due	  
to	   the	   administration	   of	   antiretroviral	   therapy	   (ART).	   HIV	   infection	   has	   now	   become	   a	  
chronic	   disease	   with	   people	   living	   with	   HIV	   (PLHIV)	   now	   surviving,	   aging	   and	   requiring	  
lifelong	  care	  and	  treatment.	  24	  
Across	  all	  age	  groups,	  PLHIV	  have	  increased	  risk	  of	  chronic	  complications	  and	  comorbidities	  
(non-­‐communicable	  diseases	  and	  mental,	  neurological	  and	   substance-­‐use	  disorders)	  which	  
can	  be	  pre-­‐existing,	  HIV	  associated,	  or	  due	  to	  aging.25-­‐27	  
Benign	   Parotid	   Lymphoepithelial	   Disease	   and	   Mucocoeles	   are	   well	   documented	   to	   be	  
associated	   with	   HIV	   infection.28,29	   Studies	   have	   also	   shown	   that	   the	   incidence	   of	   AIDS-­‐
defining	   malignancies	   has	   been	   on	   the	   decline.26,27	   However,	   deaths	   due	   to	   non-­‐AIDS-­‐
defining	  illnesses	  have	  been	  on	  the	  rise.	  These	  so-­‐called	  non-­‐AIDS-­‐defining	  cancers	  (NADCs)	  
include	  cancers	  of	  the	  lung,	  liver,	  kidney,	  anus,	  head	  and	  neck,	  and	  skin,	  as	  well	  as	  Hodgkin's	  




susceptibility	   to	   immunosuppression,	  opportunistic	  and	  viral	   infections	  which	   render	   them	  
at	  higher	  risk	  for	  cancers	  that	  are	  caused	  by	  oncogenic	  viruses.29,30	  
Literature	   has	   demonstrated	   an	   increased	   risk	   associated	   with	   HIV	   positivity	   and	  
development	  of	   squamous	   cell	   carcinoma	   in	   the	  head	  and	  neck	   region.31	   In	  particular,	   for	  
salivary	  gland	  cancers,	  Purgina	  et	  al31,	   in	  2011,	  showed	   in	   their	   review	  of	   the	   literature	  on	  
head	  and	  neck	  carcinomas	  in	  HIV	  positive	  patients,	  the	  cancer	  risk	  for	  patients	  with	  HIV	  was	  
greatest	   for	   developing	   Lymphoepithelial	   carcinoma	   and	   further	   determined	   that	   patients	  
with	  HIV	  also	  had	  a	  significant	  risk	  of	  developing	  Squamous	  cell	  carcinoma.	  In	  this	  study	  they	  
also	   reported	   that	   when	   patients	   with	   HIV	   did	   have	   confirmed	   primary	   squamous	   cell	  
carcinoma	  of	  the	  salivary	  gland	  it	  histologically	  was	  high	  grade	  and	  keratinizing	  in	  nature.31	  
The	  WHO	  classification	  of	  salivary	  gland	  tumours	  defines	  Lymphoepithelial	  carcinoma	  as	  an	  
undifferentiated	   carcinoma	  with	   prominent	   non–neoplastic	   lymphoplasmalytic	   infiltrate.	   It	  
occurs	   in	   less	   than	   1%	   of	   the	   salivary	   gland	   tumours	   in	   the	   general	   population.	   It	   is	   seen	  
more	  commonly	  in	  the	  Asian	  and	  in	  the	  Inuit	  (Eskimo)	  populations.	  There	  is	  almost	  a	  100%	  
association	  with	  lymphoepithelial	  carcinomas	  and	  Epstein	  Barr	  Virus	  (EBV)	  in	  endemic	  areas	  
but	   it	   is	   absent	   from	   Lymphoepithelial	   carcinomas	   in	   the	   salivary	   glands	   in	   non–endemic	  
areas.	   What	   was	   found	   particularly	   interesting	   is	   that	   LEC	   is	   morphologically	  
indistinguishable	  from	  the	  more	  common	  nasopharyngeal	  carcinoma	  (NPC),	  which	  has	  also	  
been	   found	   to	   be	   elevated	   in	   patients	   with	   HIV.30,31,32	   It	   has	   also	   been	   reported	   that	  
individuals	   with	   acquired	   immunodeficiency	   syndrome	   (AIDS)	   in	   the	   American	   population	  
had	   strongly	   elevated	   risks	   for	   lymphoepithelial	   carcinoma	   along	   with	   squamous	   cell	  
carcinoma.30,	   31	   This	   was	   mirrored	   in	   India	   where	   it	   has	   been	   shown	   that	   there	   is	   also	   a	  
moderately	   increased	   risk	   of	   developing	   a	   non-­‐AID’s	   defining	   salivary	   gland	   cancer	   in	  
patients	  with	  HIV	  infection.32	  
	  
RESEARCH	  QUESTION	  
This	  particular	  area	  of	  study	  has	  not	  previously	  been	  undertaken	  in	  Southern	  Africa,	  which	  in	  
no	   doubt	   is	   the	   heart	   of	   the	   pandemic	   and	   home	   to	   the	   world’s	   largest	   Anti-­‐retroviral	  




Further,	  the	  apparent	  variable	  distribution	  of	  salivary	  gland	  tumors	  in	  South	  Africa	  and	  Africa	  
as	  a	  whole	  makes	   it	   imperative	   for	   the	  need	   to	  evaluate	   the	  pattern	   in	   in	   this	  part	  of	   the	  
world,	  as	  data	  from	  other	  parts	  of	  the	  world	  do	  not	  represent	  patterns	  of	  disease	  found	  here	  
in	  South	  Africa	  or	   in	  Africa	  at	   large.	  The	  paucity	  of	  data	  on	  this	  group	  of	  tumours	   in	  South	  
Africa	   makes	   this	   retrospective	   review	   even	   more	   relevant.	   This	   study	   therefore	   aims	   to	  
document	   the	   pattern	   of	   salivary	   neoplasms	   in	   Durban,	   Kwazulu	   Natal,	   South	   Africa	   and	  
further	   evaluate	   if	   HIV	   infection	   has	   had	   any	   impact	   on	   the	   presentation	   and	   treatment	  
outcomes	  of	  Salivary	  Gland	  Tumours	  in	  the	  ART	  era.	  	  
The	  results	  of	  the	  study	  will	   inform	  the	  body	  of	  knowledge	  on	  the	  aspects	  of	  this	  subset	  of	  
Head	  and	  Neck	  Tumours	  in	  HIV	  positive	  and	  negative	  individuals	  in	  an	  area	  with	  high	  rates	  of	  
HIV	  infection.	  In	  doing	  so,	  this	  will,	  in	  future,	  enable	  faster	  recognition,	  diagnosis	  and	  hence	  
better	  management	  of	  affected	  individuals.	  
Furthermore,	   this	   is	   the	   first	   study	   of	   this	   nature	   on	   salivary	   gland	   pathology	   from	   South	  
Africa	  and	  it	   is	  believed	  it	  will	  serve	  as	  a	  platform	  for	  further	  research	  and	  development	  in	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The link between HIV and epithelial 
salivary gland neoplasms 
 
The devastating effect of the global human 
immunodeficiency virus (HIV) epidemic 
has been significantly reduced, largely due 
to the administration of antiretroviral 
therapy (ART). HIV infection has now 
become a chronic disease, and people 
living with HIV (PLHIV) are now surviving, 
ageing and requiring lifelong care and 
treatment.[1-3] 
Studies have shown that the incidence of 
acquired immunodeficiency virus (AIDS) -
defining malignancies has been on the 
decline and deaths due to non-AIDS-
defining illnesses, such as non-AIDS 
defining cancers (NADC), have been on 
the rise. These so-called NADCs include 
cancers of the lung, liver, kidney, anus, 
head and neck, and skin, as well as 
Hodgkin’s lymphoma.[3] The reasons why 
Summary 
 
Objectives. Determine and compare the 
demographics and presentation of salivary 
gland tumours in two groups of patients 
infected with human immunodeficiency virus 
(HIV): those on antiretroviral therapy (ART), 
those not on ART, and uninfected patients, (ii) 
Ascertain if HIV infection and access to ART 
has altered the histopathological presentation 
of salivary gland tumours in the patient 
population, (iii) Determine if HIV infection and 
its treatment is associated with a change in 
morbidity, compared to uninfected patients 
following definitive treatment of salivary gland 
neoplasms. 
Method. A retrospective chart analysis was 
conducted of all the submandibular and parotid 
gland surgeries undertaken by the Department 
of Otorhinolaryngology at Inkosi Albert Luthuli 
Hospital, a quaternary state hospital. This 
review was done for surgeries completed from 
July 2008 to June 2017 (data for 2003 to 2008 
could not be located on site).  
Results. Between July 2008 and June 2017, 
a total of 185 surgeries had been undertaken: 
100 parotidectomies and 85 submandibular 
gland excisions. HIV-positive patients are likely 
to present with malignant epithelial parotid 
gland tumours at a younger age than their HIV-
negative counterparts, p=0.032. Conclusion. 
HIV-positive patients are likely to present with 
a malignancy of the parotid gland at a younger 
age. As clinicians, we need to have a high 
index of suspicion when assessing and 
managing these patients in the future, and 





PLHIV have an increased risk of cancer 
could be their susceptibility to 
immunosuppression, and opportunistic and 
viral infections, which render them at 
higher risk of cancers that are caused by 
oncogenic viruses.[4] 
 
The literature demonstrates an increased 
risk associated with HIV positivity and the 
development of squamous cell carcinoma in 
the head and neck region.[5-7] Regarding 
salivary gland cancers, in particular, it has 
recently been reported that individuals with 
AIDS in the North American population had 
strongly elevated risks for lymphoepithelial 
carcinoma and squamous cell 
carcinoma.[5,7] This finding was mirrored in 
India, where there was found to be a 
moderately increased risk of developing 
non-AIDS-defining salivary gland cancer in 
patients with HIV infection.[8] 
 
It has also been postulated that combination 
ART (cART) may have a role in the 
development of certain cancers. A review of 
cART and cancer risk by Borges in 2017 
reported that, when cART is initiated 
immediately, the risk of developing an 
NADC might be reduced by 29% compared 
to patients for whom cART initiation is 
deferred. However, Borges does admit that 
further study in this area is required.[9] 
 
From Durban, South Africa, Madiba et al. 
reported in 2009 that HIV-infected patients 
without AIDS-defining criteria have a 
surgical course similar to that of uninfected 
patients.[10] In the same study by Madiba et 
al., the outcome of all surgery except 
anorectal surgery, including post-
procedural complications, is similar for 
HIV-infected and uninfected patients, 
regardless of the site of surgery.[10] 
In our study, we wanted to determine if 
our findings echoed the findings of the 
studies mentioned above, if our patient 
population differed and, if so, how they 
differed. These particular areas of study 
have not been investigated before in 
southern Africa, which is the epicentre of 
the HIV pandemic and home to the world’s 
largest ART programme.[11] This study, 
therefore, endeavoured to document the 
pattern of salivary neoplasms in Durban, 
KwaZulu-Natal, South Africa, and, 
furthermore, evaluate if HIV infection has 
had any impact on the presentation and 
treatment outcomes of salivary gland 
tumours in the ART era.  
The results of the study will enlighten us 
about aspects of this subset of head and 
neck tumours in HIV-positive and -negative 
individuals in an area with high rates of 
HIV infection and, in doing so, the study 
will enable us to recognise, diagnose and, 
hence, manage affected individuals better 
and faster in the future. 
 
Materials and methods 
 




obtained from the Biomedical Research 
Ethics Committee of the University of 
KwaZulu-Natal and the KwaZulu-Natal 
Health Research Committee (BE464/16). 
 
A retrospective chart analysis was planned 
for data from 2003, when the Inkosi Albert 
Luthuli Hospital (IALCH) Department of 
Otorhinolaryngology service started, to 
June 2017. This involved analysing theatre 
records and treatment charts of patients 
who presented with submandibular or 
parotid salivary gland tumours requiring 
surgery. Unfortunately, charts for patients 
from 2003 to July 2008 could not be 
traced, so the analysis was undertaken for 
data from July 2008 to June 2017.  
 
All patients who presented for surgical 
removal of their parotid or submandibular 
gland tumours at IALCH during the 
designated period, with documented HIV 
results, were included in the study. 
Patients with undocumented HIV results, 
or with non-epithelial and non-neoplastic 
disease, were excluded. Patients with 
metastatic disease were not included, as 
they were often operated on in conjunction 
with additional surgical disciplines, in other 
theatres, which made it difficult to trace 




Continuous variables were expressed as 
mean ± standard deviation (SD) or 
medians (interquartile range) and 
compared using the Student’s t-test or the 
Wilcoxon test, as appropriate. Proportions 
and categorical variables were compared 
using Pearson’s chi-square test or Fisher’s 
exact test, as appropriate. All analyses 
were performed using SPSS Version 25 
(IBM Corp. Released 2018. IBM SPSS 
Statistics for Windows, Version 25.0. 




Our study included 184 surgeries 
performed between July 2008 and June 
2017:142 parotidectomies and 42 
submandibular gland (SMG) removals. 
Patient ages ranged from 1 to 88 years, 
with an average age of 44.14 (SD ± 18.70 
years). Using Shapiro-Wilk’s test for 
normality, patient age was found to be 
normally distributed (p=0.191) (Table 1). In 
our patient population, 30 (16.30%) 
patients were HIV-positive and 102 
(55.43%) were HIV-negative; the HIV 
results of a further 52 (28.26%) patients 
were unknown.  
 
Of the 25 HIV-positive patients who had 
undergone parotid surgery, 22 (88.0%) 
were found to have epithelial salivary 
gland neoplasms (ESGN). In the SMG, 3 
(60.0%) of a total of 5 HIV-positive patients 
were found to have ESGN. All 3 of the 
HIV-positive patients presenting with 




benign disease. There was no significant 
difference in the mean age of presentation 
in HIV-positive (34.3 years) compared to 
HIV-negative (31 years) patients with 
ESGN in the SMG (p=0.48).  There was a 
statistically significant difference between 
the mean age of patients presenting with 
malignant epithelial parotid gland 
neoplasms (MEPGN) who were HIV-
positive (38.7 years), and that of patients 
who were HIV-negative (47.9 years) 
(p=0.032). However, there was no 
statistically significant difference between 
the mean ages of HIV-positive patients 
(40.9 years) and HIV-negative (39.3 years) 
patients with benign epithelial parotid 
gland neoplasms (BEPGN) (p=0.74) 
(Table 4). There appears to be an overall 
increased risk for an HIV-positive patient to 
develop a malignant tumour in the parotid 
gland (relative risk 1.41, 95% confidence 
interval (CI) 0.75 to 2.66, p=0.29). 
 
Among the study group there were 100 
(54.31%) female and 84 (45.65%) male 
patients. More female patients (25, 
60.98%) than male patients (16, 39.02%) 
presented with malignant epithelial 
tumours in the parotid gland and this 
difference was found to be statistically 
significant (p=0.0162). The mean age of 
male HIV-positive patients presenting with 
parotid ESGN was 41.63 years (SD ± 
6.97), which was higher than the mean 
age of their female counterparts, which 
was 38.41 years (SD ±13.53). However, 
using a Welch’s t-test that corrected for the 
difference in numbers of male and female 
patients, this difference was found to be 
not statistically significant (p=0.44). The 
mean age of HIV-positive female patients 
presenting with MEPGN was 37.40 (SD ± 
8.82), and the mean age of HIV-positive 
male counterparts was 40.25 years (SD ± 
10.18). Again, the Welch’s t-test found that 
this difference was not statistically 
significant (p=0.67).  
 
Out of a total of 74 pleomorphic adenomas 
found arising from the parotid gland, 12 
(16.2%) were in HIV-positive patients. Only 
1 (33.33%) of the 3 patients presenting 
with basal cell adenoma in the parotid 
gland was HIV-positive. The total number 
of patients presenting with pleomorphic 
adenoma arising from the SMG was 14, 
and only 3 (21.43%) of those patients were 
HIV-positive (Tables 2 & 3 respectively). 
 
In our patient population, HIV-positive 
patients with epithelial malignancies had a 
mean CD4 count of 385.89 cells/mm3 (SD 
± 161.72). This CD4 count is lower than 
the mean CD4 count of 407.92 cells/mm3 
(SD ± 119.04) found in HIV-positive 
patients presenting with benign epithelial 
salivary gland tumours; however, this 
difference was not found to be statistically 
significant (p=0.72) – this was determined 
using the Welsch’s t-test, because we had 
different sample sizes and variances.  
 
The World Health Organization defines 




established HIV-infection in adults.[12] We 
considered the CD4 counts of HIV-positive 
patients with benign and malignant 
disease in the parotid gland and grouped 
them according to this classification, using 
the Fischer’s exact test. When comparing 
the CD4 ranges of these two groups, the 
p-value was found to be 0.55 (Table 5). No 
patients in either group presented with 
severe immunosuppression (CD4<200). 
 
Of the 30 HIV-positive patients, 14 
(46.67%) were on highly active 
antiretroviral therapy (HAART); 15 (50%) 
of the HIV-positive patients were not on 
HAART, and this information was not 
documented for 1 (3.33%) patient. Three 
(33.33%) of the 9 patients with MEPGN 
were on HAART, and 7 (53.85%) of the 12 
patients presenting with benign epithelial 
salivary gland neoplasms were on HAART.  
 
Of the 184 patients who underwent surgery, 
the final histology reports of 144 (78.26%) 
reported that they had ESGN (Tables 3 & 
4). Patients’ final histology reports showed 
only 3 types of benign epithelial tumours 
arising from the parotid gland, and 1 type of 
benign epithelial tumour from the SMG. 
Malignant epithelial disease was more 
varied, with 6 different pathologies reported 
in the parotid gland and 4 in the SMG.  
 
Epithelial-myoepithelial carcinoma was the 
most common malignant epithelial tumour 
found in the SMG, representing 3 (50%) of 
total malignant tumours identified. The most 
common MEPGN was mucoepidermoid 
carcinoma, in 10 (24%) patients, followed 
closely by epithelial-myoepithelial 
carcinoma, representing 9 (22%) 
malignancies (Tables 2 & 3). 
 
After surgical excision, normal glands were 
reported in 3 patients; however, for 1 of 
those in the parotid gland, an adjacent 
lymph node was reported positive for 
carcinoma of possible cutaneous origin, 
and for 1 of those in the SMG, an adjacent 
lymph node was reported positive for 
adenocarcinoma. Of the 42 patients who 
underwent SMG excision, 1 (3.45%) HIV-
negative patient had no documented post-
operative pathology report. We believe this 
patient was subsequently registered under 




In our study population, HIV-positive 
patients did not show any increased risk of 





In this study, 47 (32.64%) patients, out 
of a total number of 144, had 
malignant epithelial tumours. The 
number of patients with epithelial 




(33.03%), which is higher than the 
rates reported in large population 
studies for northern Europe and 
northern America, in which parotid 
malignancies accounted for only 11 to 
17% of parotid tumours.[13-17] 
 
Pleomorphic adenoma was found in 74 
(59.68%) of patients with epithelial 
parotid neoplasms. Warthin’s tumour 
accounted for 6 (7.23%) of BEPGN in 
our series, which is less than the 15 - 
22% reported in Western literature.[17] 
The reason may be because Warthin’s 
tumour has been found to be 
uncommon in Black African 
populations.[18] 
 
In our study, the rate of malignancy in 
the SMG was 30%, and appears to be 
lower than rates reported by large 
American and European studies, which 
report rates of malignancy of the SMG 
between 40 and 66%.[19-22] In the SMG, 
all 6 (100%) of our patients who 
presented with epithelial malignancy 
were female. Benign disease occurred 
with equal frequencies in male and 
female patients. None of the patients 
presenting with epithelial malignancies 
in the SMG were HIV-positive.  
 
The most common benign and 
malignant epithelial neoplasms in our 
population group were pleomorphic 
adenoma and epithelial-myoepithelial 
carcinoma, identified in 88 (90.72%) 
and 12 (25.53%) of patients 
respectively, out of a total number of 
144 patients. The second-most-
common epithelial malignancy was 
mucoepidermoid carcinoma, with 11 
(23.40%) patients identified in our 
population group. Epithelial-
myoepithelial carcinoma is a rare 
salivary gland malignancy that 
represents <1% of all salivary gland 
malignancies. It has been reported to 
have a slight female predominance, 
which was echoed in our study 
population.[23,24] This could further 
explain the higher rates of MEPGN in 
females compared to males in our 
study population compared to other 
studies from the rest of the world, 
including Africa.(13-15,17,25-17) 
 
The most common primary MEPGN 
was mucoepidermoid carcinoma; this 
was in keeping with other population-
based studies from the rest of the 
world, including Africa.[13-17,19,20,25-27) 
 
Studies have confirmed that the 
incidence of AIDS-defining cancers 
(ADC) has been on the decline; 
however, deaths due to non-AIDS-
defining illnesses have been on the 
rise.[3] These so-called NADCs include 
cancers of the lung, liver, kidney, anus, 
head and neck, and skin, as well as 
Hodgkin’s lymphoma.[3] The reasons 
for PLHIV having an increased risk of 




immunosuppression, and opportunistic 
and viral infections, which render them 
at higher risk for cancers that are 
caused by oncogenic viruses, such as 
human papillomavirus and Epstein 
Barr virus.[4,5] 
 
Deeken et al. (2012), in a review of 
various epidemiological studies from 
France, the United Kingdom, 
Switzerland and the United States, 
observed increased rates of NADCs, 
whilst ADCs were found to have 
declined in some areas, up to threefold 
from 1995 to 2005. They also report 
that the risk of a PLHIV older than 40 
years developing an NADC of any 
kind, is 12 times higher than the risk of 
the general population. They state that 
the duration of HIV infection is 
associated with an increased risk of 
developing an NADC, with a reported 
increased risk ratio of 1.20 for every 
year of HIV infection. Furthermore, in 
the United States, NADCs have been 
found to occur more commonly in men, 
with women displaying no higher rates 
of NADCs than the general 
population.[3] This finding regarding 
malignant disease was not replicated 
in this study’s population of HIV-
positive patients. Malignant disease 
was found more commonly in female 
patients, with 5 (55.56%) female 
patients found to have a malignant 
neoplasm arising from the parotid 
gland, and only 4 (44.44%) HIV-
positive male patients presenting with 
a malignancy. 
  
In this study, the mean age of patients 
presenting with benign epithelial 
disease and malignant epithelial 
disease was 42.77 (SD ± 17.68 years) 
and 53.13 (SD ± 15.53 
years) respectively. We found that 
HIV-positive patients presenting with 
MEPGN presented significantly 
younger than their HIV-negative 
counterparts (p=0.032). The mean age 
of the HIV-positive group was 38.67 
(SD ± 8.94 years), and that of the HIV-
negative group, 47.89 (SD ± 11.23 
years) (Table 4). This finding appears 
to be in keeping with results reported 
by Purgina et al. (2011) in a review 
article on carcinomas arising from the 
head and neck region of HIV-positive 
patients. They found that mucosal 
squamous cell carcinoma, 
nasopharyngeal carcinoma, 
lymphoepithelial carcinoma of the 
salivary glands and Meckel cell 
carcinoma in the head and neck region 
presented at a younger age in HIV-
positive patients. They report, 
furthermore, that HAART did not 
appear to alter the incidence of head 
and neck carcinomas in HIV-positive 
patients, as it did in HIV-positive 
patients with Kaposi sarcoma, but 
acknowledge that this is an area in 
which further study is required.[7] The 




malignancy, and on HAART, identified 
in our study was 3 (12%); this number 
is too small to draw any of the above 
conclusions and, hence, no further 
calculations were carried out in this 
area.  
 
The most common benign epithelial 
salivary gland neoplasm amongst all 
25 HIV-positive patients in this study 
was pleomorphic adenoma, which was 
found in 16 (64.00%) patients. The 
most common malignant epithelial 
salivary gland neoplasm amongst our 
HIV-positive patient population, in the 
parotid gland, was shared by 
mucoepidermoid and epithelial-
myoepithelial carcinoma, with 4 
patients each presenting with the 
above representing (44.44% with each 
malignancy). The remaining 1 
(11.11%) HIV-positive patient 
presented with acinic cell carcinoma. 
This finding is in contrast with findings 
reported by Purgina et al. (2011), 
whose study found that 
lymphoepithelial carcinoma and 
squamous cell carcinoma were the 
most common salivary gland tumours 
in their HIV-positive population.[7]. A 
2010 study by Shebl et al. in India 
found a moderately elevated risk for 
developing a malignant salivary gland 
tumour for PLHIV.[5]. In our series, none 
of the HIV-positive patients presented 
with lymphoepithelial carcinoma or 
squamous cell carcinoma of the 
parotid or SMG. 
 
One HIV-positive patient with a benign 
epithelial neoplasm had documented 
postoperative sepsis; however, due to 
this small number it was evident that 
HIV infection did not play a role in the 
development of postoperative sepsis 
or wound breakdown in our patient 
population, in keeping with findings by 





From the discussion above, we 
conclude that HIV-positive patients are 
more likely to present with a 
malignancy of the parotid gland at a 
younger age than their HIV-negative 
counterparts. As clinicians, we need to 
have a high index of suspicion when 
assessing such patients and avoid any 
unnecessary delays in management.  
 
To the best of our knowledge, this is 
the first study of this nature on salivary 
gland pathology in South Africa, and it 
will serve as a platform for further 
research and development in this 





Table 1: Demographic data 
 
 Parotid Submandibular 
N (%) 95% CI N (%) 95% CI 
AGE 
<20 15 (10.1) 5.01-15.06 6 (14.3) 3.7-24.9 
21 – 30 18 (12.7) 7.22-18.18 9 (21.4) 9.0-33.8 
31 – 40 22 (15.5) 9.55-21.45 6 (14.3) 3.7-24.9 
41 - 50 32 (22.5) 15.63-29.37 10 (23.8) 10.9-36.7 
51 – 60 22 (15.5) 9.55-21.45 6 (14.3) 3.7-24.9 
61 - 70 20 (14.1) 8.38-19.82 3 (7.1) 0.7-14.9 
>70 13 (9.2) 4.45-13.95 2 (4.8) 1.7-11.3 
Total 142 (100.0)  42 (100.0)  
GENDER 
Male 62 (43.7) 35.54-51.86 22 (52.4) 37.3-67.5 
Female 80 (56.3) 48.14-64.46 20 (47.6) 32.5-62.7 
Total 142 (100.0)  42 (100.0)  
HIV STATUS 
Positive 25 (17.6) 11.34-23.86 5 (11.9) 2.1-21.7 
Negative 73 (51.4) 43.18-59.62 29 (69.0) 55.0-83.0 
Unknown 44 (30.1) 22.56-37.64 8 (19.0) 7.1-30.9 
Total 142 (100.0)  42 (100.0)  
*CD4 
None 4 (16.0) 1.63-30.37 1(20.0) 15.1-55.1 
Mild 8 (32.0) 13.71-5029 0(0.0) 0.0-0.0 
Advanced 11 (44.0) 24.54-63.46 2(40.0) 2.9-82.9 
Severe 0 (0.0) 0.0-0.0 1(20.0) 15.1-55.1 
Unknown 2 (8.0) 2.63-18.63 1(20.0) 15.1-55.1 
Total 25 (100.0)  5(100.00  
ART 
Yes 11 (44.0) 24.54-63.46 3 (60.0) 17.1-102.9 






1 (4.0) 3.68-11.68 0 (0.0) 0.00-0.00 
Total 25 (100.0)  5 (100.0)  
* CD4 classification/grade of immunodeficiency[12] 
 
Table 2: Histology and Distribution of Parotid gland Neoplasms 
 
Tumour type/ 
pathology reported N 










































neoplasms 83 36 47 13 44 26 8 14 12 18 15 9 7 
Pleomorphic 
adenoma 74 30 44 12 41 21 8 14 11 16 14 6 5 
Warthin’s tumour 6 5 1 0 2 4 0 0 0 1 1 3 1 
Monomorphic 
adenoma  3 1 2 1 1 1 0 0 1 1 0 0 1 
Malignant epithelial 




9 2 7 4 3 2 0 2 1 2 2 0 2 
Mucoepidermoid 
carcinoma  10 4 6 4 4 2 0 1 4 4 0 1 0 
Adenoid cystic 
carcinoma 2 0 2 0 1 1 0 0 0 0 0 1 1 
Adenocarcinoma  5 2 3 0 4 1 0 0 0 1 2 2 0 
Acinic cell-
carcinoma  6 2 4 1 4 1 0 0 3 1 1 1 0 
Carcinoma ex – 
pleomorphic 
adenoma 
3 1 2 0 1 2 0 0 1 1 1 0 0 
Squamous cell 
carcinoma  5 4 1 0 1 4 0 0 0 1 0 2 2 
Metastatic 
carcinoma 1 1 0 0 0 1 0 0 0 0 0 0 1 
Benign non-





pathology reported N 









































Spindle cell Lipoma 1 1 0 0 0 1 0 0 0 0 0 1 0 
Lipoma 1 0 1 0 1 0 0 0 0 1 0 0 0 
Calcifying fibrous 
pseudotumor 1 1 0 0 1 0 1 0 0 0 0 0 0 
Giant cell fibroma 1 0 1 0 0 1 1 0 0 0 0 0 0 
Malignant non-
epithelial neoplasms 6 4 2 2 4 0 4 1 0 1 0 0 0 
Lymphoma 2 1 1 1 1 0 2 0 0 0 0 0 0 
Rhabdomyosarcoma 2 1 1 0 2 0 2 0 0 0 0 0 0 
Parotid synovial 
sarcoma 1 1 0 0 1 0 0 1 0 0 0 0 0 
Neuroendocrine 
carcinoma 1 1 0 1 0 0 0 0 0 1 0 0 0 
Non-neoplastic 
lesions 9 4 5 2 5 2 1 0 1 3 1 3 0 
Fatty infiltration 0 0 0 0 0 0 0 0 0 0 0 0 0 
Chronic sialadenitis  1 1 0 0 1 0 0 0 0 1 0 0 0 
Adipose metaplasia  1 0 1 0 0 1 0 0 0 0 0 1 0 
Chronic 
inflammation 1 1 0 0 1 0 0 0 0 0 1 0 0 
Cyst  3 2 1 1 2 0 1 0 0 1 0 1 0 
Reactive lymphoid 
hyperplasia  1 0 1 0 0 1 0 0 1 0 0 0 0 





Table 3: Histology and Distribution of Submandibular gland Neoplasms 
 
















































neoplasms 14 7 7 3 8 3 1 6 4 1 2 0 0 
Pleomorphic 








3 0 3 0 2 1 0 0 0 1 0 1 1 
Mucoepidermoid 
carcinoma 1 0 1 0 1 0 0 0 0 1 0 0 0 
Adeno 
carcinoma  1 0 1 0 1 0 0 0 0 0 0 1 0 
Squamous cell 




2 1 1 0 2 0 1 0 1 0 0 0 0 
Schwannoma  1 1 0 0 1 0 0 0 1 0 0 0 0 




0 0 0 0 0 0 0 0 0 0 0 0 0 
Non-neoplastic 
lesions 20 14 6 1 14 5 4 3 1 7 3 1 1 
Fatty infiltration  1 1 0 0 0 1 0 0 0 0 1 0 0 
Chronic 
sialadenitis 11 8 3 1 8 2 1 2 1 5 1 1 0 
Chronic 
inflammation  1 0 1 0 1 0 0 0 0 0 0 0 1 
Cyst  2 1 1 0 2 0 1 1 0 0 0 0 0 








1 0 1 0 1 0 0 0 0 1 0 0 0 
Normal gland  1 1 0 0 1 0 0 0 0 1 0 0 0 
*No result 1 1 0 0 1 0 0 0 0 0 1 0 0 





Table 4: Mean age of HIV positive and HIV negative individuals presenting with an 





Mean age ± (SD) 
p-value 




































*The Welsch’s t-test is an adaptation of the Student’s t-test, which is used when two samples 
have unequal variances and unequal sample sizes. 
 
Table 5: Immunosuppression vs benign and malignant epithelial neoplasms 
 
Parotid gland None (CD4>500) 
Mild 
immunosuppression 
(CD4 350 – 499) 
Advanced 
immunosuppression 




neoplasms 3 5 4 
0.55 Malignant epithelial 








1. Joint United Nations Programme on 
HIV/AIDS. 2012 UNAIDS Report on the 
Global AIDS Epidemic 
.http://www.unaids.org/en/resources/docum
ents/2012/20121120_UNAIDS_Global_Rep
ort_2012 (accessed 4 October 2017). 
2. World Health Organization . Scoping 
consultation on chronic comorbidities in 
people living with HIV Meeting report - 8-9 
July 2014 World Health Organization, 
Geneva, Switzerland . 
http://www.who.int/hiv/pub/arv/consultation-
comorbidities-plhiv/en/ (accessed 20 
October 2017). 
3. Deeken JF, Tjen-A-Looi A, Rudek M., 
Okuliar C, Young M, Little RF, et al. The 
rising challenge of non-AIDS-defining 
cancers in HIV-infected patients. Clinical 
Infectious Diseases 2012; 55(9): 1228-
1235. 
4.Frisch M, Biggar RJ, Engels EA, Goedert 
JJ. Association of cancer with AIDS-related 
immunosuppression in adults. Journal of the 
American Medical Association 2001; 
285(13): 1736-1745. 
5. Shebl FM, Bhatia K, Engels EA. Salivary 
Gland and Nasopharyngeal cancers in 
individuals with acquired immunodeficiency 
syndrome in the United States. International 
Journal of Cancer 2010; 126(10): 2503-
2508. 
6. McLemore MS, Haigentz M Jr, Smith RV, 
Nuovo GJ, Alos L, Cardesa A, et al. Head 
and Neck Squamous Cell Carcinomas in 
HIV-Positive Patients: A Preliminary 
Investigation of Viral Associations. Head 
and Neck Pathology 2010; 4(2): 97-105. 
7. Purgina B, Pantanowitz L, Seethala RR. 
A Review of Carcinomas Arising in the 
Head and Neck Region in HIV-Positive 
Patients. Pathology Research 
International 2011; 2011(469150): . 
8. Godbole S V., Nandy K, Gauniyal M, 
Nalawade P, Sane S, Koyande S, et al. HIV 
and cancer registry linkage identify a 
substantial burden of cancers in persons 
with HIV in India.Medicine (Baltimore) 2016; 
95(37): . 
9. Borges ÁH. Combination antiretroviral 
therapy and cancer risk.Current Opinion in 
HIV and AIDS 2017; 12(1): 12-19. 
10. Madiba TE, Muckart DJJ, Thomson SR. 
Human immunodeficiency disease: How 
should it affect surgical decision making? 
. World Journal of Surgery 2009; 33(5): 899-
909. 
11. Joint United Nations Programme on HIV 
and AIDS. UNAIDS Report on South Africa . 
http://www.unaids.org/en/regionscountries/c
ountries/southafrica (accessed 20 October 
2017). 
12. World Health Organisation . Interim 
WHO clinical staging of HIV/AIDS and 
HIV/AIDS case definitions for 
surveillance.Switzerland: WHO publications; 
2005. 
https://www.who.int/hiv/pub/guidelines/clinic
alstaging.pdf (accessed 20 March 2018).  
13. Hill AG. Major salivary gland tumours in 
a rural Kenyan hospital. East African 
Medical Journal 2002; 79(1): 8-10. 
14. Pinkston JA, Cole P. Incidence Rates of 
Salivary Gland Tumors: Results from a 
Population-Based Study. Otolaryngology-





15. Eveson JW, Cawson RA. Salivary gland 
tumours. A review of 2410 cases with 
particular reference to histological types, 
site, age and sex distribution. Journal of 
Pathology 1985; 146(1): 51-58. 
16. Eneroth C-M. Salivary gland tumors in 
the parotid gland, submandibular gland, and 
the palate region.Cancer 1971; 27(6): 1415-
1418. 
17. Van Lierop A, Fagan JJ. Parotidectomy 
in Cape Town - A Review of Pathology and 
Management . South African Journal of 
Surgery 2007; 45(3): 96 - 103. 
18.  Hatzitheofilou C, Lakhoo M, 
Charalambides D, Parekh D. Warthin's 
tumour in a black patient. A case 
report. South African Journal of 
Surgery 1988; 26(4): 171-172. 
19.  Shah JP, Ihde JK. Salivary gland 
tumors. Current Problems in Surgery 1990; 
27(12): 775-843.   
20. Spiro RH. Salivary neoplasms: 
Overview of a 35-year experience with 
2,807 patients. Head and Neck 
Surgery 1986; 8(3): 177-184. 
21. Spiro RH, Hajdu ST, Strong EW. 
Tumors of the submaxillary gland. American 
Journal of Surgery 1976; 132(4): 463-468. 
22. Jones SA. Malignant Tumours of the 
Salivary Glands . Gleeson M,Michael J, 
Jones, Nicholas S, Clarke, Ray et al 
(eds). Scott-Brown’s Otolaryngology: Head 
and Neck Surgery. , 7 ed. London: CRC 
Press; 2008. pp. 2504 - 2505. 
23. Chaurasia A, Katheriay G. Epithelial 
myoepithelial carcinomas of parotid gland-a 
case report. Journal of Oral Medicine, Oral 
Surgery, Oral Pathology and Oral 
Radiology 2016; 2(3): 148-155. 
24. Robiony M, Avellini C, Orsaria M, Politi 
M. Epithelial-myoepithelial carcinoma of the 
parotid gland: Clinicopathological aspect, 
diagnosis and surgical consideration 
. Annals of Maxillofacial Surgery 2014; 4(1): 
99-102. 
25. Lakhoo K , Mannell A , Becker PJ. . 
Parotid tumours in black patients. The 
Baragwanath Hospital experience, 1981-
1986. South African Journal of 
Surgery 1989; 27(1): 13 - 15 . 
26. Schoeman BJ, Clifford SD. . The 
incidence of malignancy in neoplasms of the 
submandibular salivary gland.. South 
African Journal of Surgery 2007; 45(4): 134 
- 135. 
27. Theron EJ, Middlecote BD . Tumours of 
the salivary glands. The Bloemfontein 
experience. South African Journal of 




Appendix	  1:	  	  
Protocol	  Title	  of	  the	  study: Salivary	  Gland	  Tumours	  in	  the	  era	  of	  Antiretroviral	  Treatment 
Aim	  of	  the	  Study: To	  evaluate	  the	  presentation	  and	  treatment	  outcomes	  of	  Salivary	  Gland	  Tumours	  in	  the	  antiretroviral	  treatment	  (ART)	  era 
Objectives: 
• To	  describe	  and	  compare	  the	  demographics	  and	  presentation	  of	  Salivary	  Gland	  Tumours	  in	  HIV	  infected	  patients	  on	  ART,	  patients	  not	  on	  ART	  and	  uninfected	  patients	   
• To	  determine	  if	  HIV	  infection	  and	  access	  to	  antiretroviral	  treatment	  has	  altered	  the	  histopathological	  presentation	  of	  salivary	  gland	  tumours	   
• To	  determine	  if	  HIV	  infection	  and	  its	  treatment	  is	  associated	  with	  a	  change	  in	  morbidity	  when	  compared	  with	  uninfected	  patients	  following	  definitive	  treatment	  of	  Salivary	  gland	  tumours	   





The	  Link	  and	  Impact	  of	  HIV	  on	  Epithelial	  Salivary	  Gland	  
Neoplasms.	    
• The	  devastating	  effect	  of	  the	  global	  HIV	  epidemic	  has	  been	  significantly	  reduced	  largely	  due	  to	  the	  administration	  of	  Antiretroviral	  therapy	  (ART).	  HIV	  infection	  has	  now	  become	  a	  chronic	  disease	  with	  people	  living	  with	  HIV	  (PLHIV)	  now	  surviving,	  aging	  and	  requiring	  lifelong	  care	  and	  treatment.	  Across	  all	  age	  groups,	  PLHIV	  have	  increased	  risk	  of	  chronic	  complications	  and	  comorbidities	  (non	  communicable	  diseases	  and	  mental,	  neurological	  and	  substance-­‐-­‐-­‐use	   disorders),	  which	  can	  be	  pre-­‐existing,	  HIV	  associated,	  or	  due	  to	  aging.[4]	  Benign	  Parotid	  Lymphoepithelial	  Disease	  and	  Mucocoeles	  are	  well	  documented	  to	  be	  associated	  with	  HIV	  infection	  in	  the	  literature.[5,6]	  People	  living	  with	  HIV	  also	  manifest	  an	  increased	  risk	  of	  cancer.	  Their	  susceptibility	  to	  opportunistic	  and	  viral	  infections	  render	  them	  at	  higher	  risk	  for	  cancers	  that	  are	  caused	  by	  oncogenic	  viruses.[7]	   









Study	  Design: Retrospective	  Chart	  Review 
Study	  Population: All	  patients	  who	  have	  presented	  with	  Parotid	  or	  Submandibular	  Glands	  tumours	  to	  Inkosi	  Albert	  Luthuli	  Hospital	  (IALCH)	  and	  have	  been	  tested	  for	  HIV	  will	  be	  included	  in	  the	  study. 
Sampling	  Strategy: This	  is	  a	  retrospective	  chart	  review.	  All	  patients	  with	  salivary	  gland	  tumours	  who	  have	  been	  tested	  for	  HIV	  will	  be	  included	  in	  the	  sample.	  Patients	  with	  no	  documented	  HIV	  results	  will	  be	  excluded. 
Statistical	  Planning	  (variables/confounders): 
• HIV	  status	   
• CD4	   
• HAART	   
• Gender	   
• Age	  at	  presentation	   
• Primary	  site	  of	  tumour	  (Parotid/	  Submandibular	  Gland)	   
• Pre	  –	  operative	  histology	   
• Post	  operative/Final	  Histology	   





Sample	  Size:	    It	  is	  estimated	  that	  approximately	  200	  patients	  have	  been	  assessed	  with	  salivary	  gland	  tumours	  during	  but	  it	  is	  unclear	  how	  many	  of	  these	  patients	  had	  documented	  HIV	  results.	    
	  
Inclusion/	  Exclusion	  Criteria:	    Inclusion	  Criteria	  All	  patients	  presenting	  with	  Submandibular	  or	  Parotid	  Salivary	  Glands	  tumours	  at	  IALCH	  during	  the	  study	  period,	  with	  documented	  HIV	  results.	    
	  
Exclusion	  Criteria	    Patients	  without	  a	  documented	  HIV	  result	  will	  be	  excluded	  	  
Data	  Collection	  Methods	  and	  Tools:	    A	  retrospective	  chart	  analysis	  will	  be	  undertaken	  commencing	  from	  2003	  (when	  the	  IALCH	  ENT	  service	  began)	  to	  the	  present.	  This	  will	  involve	  analyzing	  theatre	  records	  and	  treatment	  charts	  of	  patients	  presenting	  with	  Submandibular	  or	  Parotid	  Salivary	  Gland	  tumours.	  A	  database	  will	  be	  created	  with	  the	  aforementioned	  data	  variables.	  The	  data	  collected	  will	  be	  simplified	  into	  a	  numerical	  binary	  code	  and	  entered	  into	  a	  SPSS	  data	  collection	  spreadsheet.	  SPSS	  statistics	  will	  be	  used	  to	  analyze	  the	  data	  as	  captured	  on	  the	  SPSS	  spreadsheet.	   




prior	  to	  writing	  this	  protocol.	  Descriptive	  statistics	  such	  as	  frequencies,	  percentages,	  mean,	  median,	  standard	  deviation	  and	  interquartile	  range	  will	  be	  used	  to	  summarize	  results.	  There	  will	  be	  three	  groups	  i.e	  HIV	  positive	  on	  treatment,	  HIV	  positive	  not	  on	  treatment	  and	  HIV	  negative.	  Data	  summaries	  will	  be	  given	  for	  each	  group	  separately.	  Depending	  on	  the	  distribution	  parametric	  or	  non-­‐-­‐-­‐parametric	  tests	  will	  be	  used.	  If	  the	  data	  is	  normally	  distributed	  ANOVA	  testing	  will	  be	  used	  and	  if	  nonparametric	  Kruskal	  Wallis	  or	  Friedmans	  ANOVA	  will	  be	  used	  for	  comparisons	  between	  two	  groups	  such	  as	  T-­‐-­‐-­‐tests	  or	  Mann-­‐-­‐-­‐	  Whitney	  tests	  will	  be	  used	  depending	  on	  distribution.	  .	  A	  P	  value	  of	  <0.05	  will	  be	  accepted	  as	  indicating	  that	  the	  difference	  between	  groups	  is	  significant.	  A	  P	  value	  of	  >0.05	  will	  considered	  as	  evidence	  in	  favour	  of	  the	  null	  hypothesis	  indicating	  that	  the	  groups	  compared	  were	  from	  the	  same	  population	  and	  the	  difference	  was	  not	  significant. 




HIV	  	  positive	  group	  receiving	  HAART	  and	  those	  not	  yet	  initiated	  on	  HAART	  	  8. Comparison	  of	  all	  tumour	  subtypes	  in	  the	  HIV	  positive	  group	  (ART	  vs	  Not	  	  on	  ART)	  and	  HIV	  negative	  group	  	  
	  
Study	  Location: Inkosi	  Albert	  Luthuli	  Hospital	  (IALCH) 
Study	  Period: Since	  records	  began	  to	  the	  present 
Limitations	  of	  the	  Study: No	  limits	  were	  identified	  to	  the	  study 
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  2:	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  Guidelines	  for	  Authorship	  for	  the	  Journal	  selected	  for	  
submission	  of	  the	  manuscript	  South	  African	  Journal	  of	  Surgery	  	  Author	  Guidelines	  
Accepted	  manuscripts	  that	  are	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  the	  correct	  format	  specified	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these	  guidelines	  will	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  author(s)	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  and	  will	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  publication.	  	  
AUTHORSHIP	  	  Named	  authors	  must	  consent	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  publication.	  Authorship	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  be	  based	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  conception,	  design,	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  drafting	  or	  critical	  revision	  for	  important	  intellectual	  content;	  and	  (iii)	  approval	  of	  the	  version	  to	  be	  published.	  These	  conditions	  must	  all	  be	  met	  (uniform	  requirements	  for	  manuscripts	  submitted	  to	  biomedical	  journals;	  refer	  to	  www.icmje.org).	  	  
CONFLICT	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  Authors	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  declare	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  sources	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  support	  for	  the	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  ETHICS	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  Research	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  approval	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17045
9 
29 M P PLEO-FNAC PLEO NEG N/A NIL 
13804
0 
88 M P MALIGNAN
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3 










47 F S CS LG MUCO CA NEG N/A NIL 
31716
7 
72 F P BLOOD 
ONLY 
PLEO U N/A NIL 
31880
1 
25 M P INCONCLUS
IVE 
PLEO NEG N/A MM PARESIS 
32033
2 
32 F P INCONCLUS
IVE 
PLEO NEG N/A MM PARESIS 
33438
7 
64 F P ?ACINIC 
/?ADENO CA 
ACINIC CELL CA U N/A NIL 
32286
8 
66 M P MIXED INFL 
CELLS 
WHARTINS U N/A NIL 
32236
8 
23 F P DUCTAL 
CELLS 
PLEO NEG N/A NIL 
11957
8 
63 F P ?PLEO SCC U N/A NIL 
33014
8 
67 M P ?PLEO PLEO NEG N/A NIL 
33692
0 
8 M P BLOOD 
ONLY 
ALL NEG N/A NIL 
32911
3 
20 M P INCONCLUS
IVE 
PLEO NEG N/A MM PARESIS 
31751
0 






58 M S PLEO NO RESULT NEG N/A MM PARESIS 
33013
9 







77 M P LG MUCO 
CA 
PLEO U N/A MM PARESIS 
33843
8 
55 F S BLOOD 
ONLY 
PLEO U N/A NIL 
22012
5 









82 F P BLOOD 
ONLY 
EM CA U N/A NIL 
33176
5 
17 F P PLEO PLEO U N/A NIL 
33170
2 





64 M P INCONCLUS
IVE 
ADENO CA NEG N/A NIL 
34240
9 
34 F P PLEO EM CA NEG N/A NIL 
31939
4 
31 M P PLEO PLEO NEG N/A NIL 
31477
3 




23 F P PLEO PLEO NEG N/A NIL 
26936
2 
57 M P PLEO PLEO NEG N/A NIL 
34439
5 
66 F S INCONCLUS
IVE 
SCC NEG N/A NIL 
34694
6 
66 F P SCC WHARTINS NEG N/A NIL 
34914
3 
42 F P MIXED INFL 
CELLS 
LG MUCO CA NEG N/A NIL 
33957
1 





52 F P PLEO PLEO NEG N/A NIL 
36104
6 
12 M P INCONCLUS
IVE 
RHABDO NEG N/A NIL 
34316
5 





11 M P PLEO PLEO NEG N/A NIL 
36051
9 




NEG N/A NIL 
29451
6 
32 M S PLEO PLEO NEG N/A MM PARESIS 
36740
3 






















16 F P BLOOD 
ONLY 
PLEO NEG N/A NIL 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
